Pfizer headquarters, in a conference room.

A very serious meeting is going on.

Of course, although it is called a meeting, it is actually more like an interrogation.

Pfizer President John Young sat in the first seat and looked directly at Skarna Slavi sitting across from him.

"Dr. Slavie, the company has given you a lot of resources and funds, not so that you can develop this kind of drug that can't even pass the first phase of clinical trials."

John Young's tone was calm, but it was stressful for Skarna Slavi, who was sitting across from him.

After all, John Young is the world's largest pharmaceutical company, and as the president of such a company, John Young is ruthless enough when he should be.

Skana Slavi took a deep breath, calmed the emotions in his heart, and then said: "President, I admit that I am a little anxious in this research and development. ”

"Of course, that doesn't mean we're a complete failure."

He regained his composure and said, "The main problem with PEFF is that it causes platelets to become more activated. ”

"Now we just need to continue to experiment with the principle of increasing the degree of platelet activation, and then modify this principle to solve this problem and retain the original thrombolytic effect of PEFF."

"The actual thrombolytic effect of PEFF, Mr. President, you should also know how good it is."

John Young smiled: "It can dissolve both thrombolysis and thrombolysis." ”

"Dr. Slavi, the drug you've researched is quite ironic."

Then he "tsk" again, "Tell me, why did there be a problem in the phase 1 clinical trial?" ”

Everyone present could hear the pity in his words.

This kind of medicine is like a planned scrap, and it is deeply loved by companies like theirs.

It's just a pity that they were unlucky, and they encountered this kind of thing in the phase 1 clinical trial.

In fact, it is mainly because the patient who has the problem has a higher degree of platelet activation, and then coupled with the impact of PEFF, it led to this clinical accident.

If these clinical volunteers are a little lucky, and these clinical volunteers don't have this kind of situation, with their Pfizer influence, it is easy to get the drug successfully launched, and even if there is a problem again, they can cover up similar news.

Anyway, as long as you can go public, you can make money.

Among their other drugs that have been marketed, there are more or less such drugs that are not specified and may cause life-threatening side effects.

Finally, John Young sat up straight and said to Skarna Slavie, "Well, Dr. Slavie, you are also our Chief Scientist and have made many great contributions to the company. ”

"This failure is a lesson, and I hope that as you just said, PEFF will be modified and then re-marketed."

“至少，这次事件带来的股价一来一回，还是让我们的股东们赚了一些钱，所以他们对你并没有太大的不满，不过我还是希望你能够在下次证明你作为辉瑞公司首席科学家的能力。 ”

Skarna Slavi breathed a sigh of relief, and a smile appeared on his face: "Rest assured, I will not disappoint the directors." ”

对于这个结果，他其实也早就有预料了，毕竟他也为公司赚过那么多的钱了，所以不可能因为这一次事件就把他开除掉，至于那名临床志愿者呢那里也无非就是打官司罢了，他们公司最不怕的就是打官司，反正临床志愿者都是签了协议的，更何况这些志愿者都是有偿的，真的打官司也只会是他们赢。

"Okay, that's the end of today's meeting, let's adjourn."

John Young made the announcement, and then he stood up first to leave, but just then, the door to the conference room suddenly opened, and his assistant ran in, and then whispered a few words in his ear.

Then those present could see that their president's face gradually deteriorated.

Everyone didn't dare to leave for a while.

John Young, on the other hand, glanced at the people present, then sat back in his seat and said, "The meeting continues." ”

Then he looked back at Skarna Slavi and said, "What is your relationship with Kingsley Weil and Li Mu?" ”

Skarna Slavi was stunned, a little puzzled.

"President, you...... Why is this question asked all of a sudden? ”

“你先回答就行了。 ”

"I ...... I don't know Li Mu very well, but I invited him to join us at the Max Planck Society's Life Sciences Conference Dinner, you know about it, as for Kingsley Weil...... Uh......"

Under the eyes of the president, Skarna Slavi could only say the contradiction between him and Kingsley Vale.

Knowing that Skana Slavie's girlfriend back then was actually snatched by this person named Kingsley Weir, everyone present wanted to laugh a little, but they didn't dare to laugh.

John Young was silent for a moment, he only knew that there was a contradiction between Skarna Slavy and Kingsley Weil, but he didn't expect it to be this contradiction, and he didn't know what to say for a while.

But in the end, he shook his head and gestured to the assistant next to him.

Then, the assistant nodded, and then said to everyone: "According to the latest intelligence, Li Mu and Kingsley Weir's team has developed a new type of thrombolytic drug, which they named RSCA. ”

"This drug has a stronger thrombolytic effect than fourth-generation thrombolytic drugs, and in addition, it is able to form a membrane on the surface of insoluble fibrin, making it smoother and therefore less prone to coagulation."

"In addition, according to the news, the biggest advantage of their new thrombolytic drug is that it is more specific, and it will only target the fibrin in the thrombus, and will not cause blood vessels to dissolve, which will lead to bleeding symptoms."

"What?!"

Skarna Slavi's eyes widened.

When the other researchers in the conference room heard the news, they couldn't sit still for a while.

"How can you develop this thrombolytic drug?"

As long as it is a person who has studied thrombolytic drugs for a certain time, they are shocked at this time.

"And I remember that Kingsley Weil approached us to develop this drug, but we refused to cooperate with him because of you, and I remember you saying that he was a liar."

John Young's brows gradually condensed: "I hope you can give me an explanation for this matter!" ”

And Skarna Slavi was already full of disbelief: "Impossible, absolutely impossible!" ”

……

Pfizer's new drug failed, and the "liar's" new drug succeeded? 》

The Most Perfect Thrombolytic Drug, RSCA? 》

"Li Mu Data Analysis Method Recreates the Power, Perfect Thrombolytic Drugs Set Off a Medical Revolution"

《……》

With the publication of the paper on RSCA in Cell, the effect of RSCA immediately set off a shock in the entire medical community, even better than Pfizer's PEFF.

After all, RSCA is the most perfect thrombolytic drug in terms of effect alone.

In the paper, people in the biomedical field once again saw Li Mu's data analysis method, showing a huge effect, just like the special issue of The Lancet.

For a time, the entire medical community was shaken by the effect of RSCA.

……

Mayo Clinic, Jason Leighton's office.

As a top cardiac surgeon, he was being interviewed by a news reporter at this time.

"Hello, Dr. Leighton."

The New York Times reporter spoke to Jason Layton with great respect that doctors and lawyers are the most respected professions in this country, let alone top doctors like Jason Layton.

"I believe that on the recent news, you should know about the failure of Pfizer's new thrombolytic drug, and the news about the most perfect thrombolytic drug researched by that mathematical genius Li Mu."

"Of course, I've seen both of them." Jason Layton nodded.

The reporter smiled slightly and then asked: "I heard that in your surgery, the need for thrombolytic drugs is generally relatively high, is this true?" ”

Jason Layton laughed, "Of course, it's true. ”

"Thrombolytic drugs are a necessary drug for cardiac surgery, because what you have to know is that once heart surgery is performed, it is very easy to form a blood clot in the patient's body - or any surgery is easy to lead to the formation of blood clots, because during and after the operation, the human body will be in a state of stress, the blood will be in a hypercoagulable state, mobilize the clotting factors in the body, and then guide the problem of blood clots."

"Especially in our cardiac surgery, the problems caused by blood clots have always affected our operations, so the main purpose of means such as cardiac angiography and cardiac CT in our surgery is to detect whether there is a blood clot problem."

"I see!" The reporter nodded.

"So, what do you think about Pfizer's PEFF and Li Mu's RSCA? Will RSCA be a success? ”

杰森·雷顿思考了片刻后，说道：“PEFF没有好说的，这种溶栓药物实在有些可笑，能够提高血小板活化程度的溶栓药物，就像是穿着裤子上厕所一样，愚蠢至极。 ”

"As for the RSCA...... I don't know how to evaluate it at the moment, but if the effect is really as stated in the paper, I would say that this will be the favorite thrombolytic drug for a cardiac surgeon like me, it is fast, efficient, and most importantly, it has a lasting effect of up to two years......"

"I would say that there is no better thrombolytic drug than this."

"So, we just need to wait for the verification of clinical trials."

"Of course, psychologically, I believe it."

"Although I haven't seen Li Mu with my own eyes, I feel in my heart that this is a magical person."

Jason Layton said with a smile.

Under the influence of Li Mu's paper, he already admired this person he had never met.

而听到杰森·雷顿这么说，记者也感慨起来，“是啊，确实是一个神奇的人，就像我刚才说的，明明是个数学天才，但是他怎么就这么全能呢？ ”

Jason Layton nodded approvingly.

……

(End of chapter)